Semaglutide is a molecule—not one interchangeable product
Semaglutide is a GLP-1 receptor agonist. Different brands, formulations and strengths are authorized for different indications. In the United States, Ozempic is a diabetes product and Wegovy is a weight-management product with specific approved indications. A diabetes brand name should not be treated as a universal synonym for medical weight treatment, and products should not be interchanged without checking their formulation, authorized use and prescribing information.
The pivotal obesity studies below used a defined semaglutide product and research protocol. They do not validate an unlabelled vial, a repackaged syringe, a compounded or “research” product, or a product whose storage history is unknown. Current DRAP status and the exact authorized presentation in Pakistan must be verified at the time of care.
Key semaglutide trials at a glance
The percentages below are group averages or event rates from specific clinical trials. They should be interpreted in the population studied and should never be converted into a guaranteed personal result.
| Trial | Population and duration | Main result | What it means clinically |
|---|---|---|---|
| STEP 1 | 1,961 adults with obesity or overweight plus a complication, without diabetes; 68 weeks | Mean weight change −14.9% with semaglutide 2.4 mg versus −2.4% with placebo | Established substantial average weight loss in selected adults without diabetes. |
| STEP 2 | 1,210 adults with obesity or overweight and type 2 diabetes; 68 weeks | Mean change −9.6% with semaglutide 2.4 mg versus −7.0% with 1.0 mg and −3.4% with placebo | Weight benefit remained meaningful, but average loss was lower in the diabetes population. |
| STEP 4 | Randomized withdrawal after a 20-week semaglutide run-in; outcomes to week 68 | From week 20 to 68, continued treatment produced another −7.9%; switching to placebo led to +6.9% regain | Stopping effective treatment without a maintenance plan commonly leads to regain. |
| SELECT | 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes; mean follow-up 39.8 months | Major cardiovascular events: 6.5% with semaglutide versus 8.0% with placebo; hazard ratio 0.80 | A 20% relative risk reduction and 1.5-point absolute difference in this specific high-risk population—not a universal claim for all patients. |
How strong was the STEP 1 weight response?
At week 68 in STEP 1, at least 5% weight loss was reached by 86.4% of participants receiving semaglutide versus 31.5% on placebo. At least 10% was reached by 69.1% versus 12.0%; at least 15% by 50.5% versus 4.9%; and at least 20% by 32.0% versus 1.7%. These responder rates show that semaglutide can produce major benefit, while the spread between thresholds confirms that individual response varies.
The 14.9% headline is the estimated average change from starting body weight, not the placebo-adjusted effect and not the percentage of patients who lost weight. The estimated treatment difference versus placebo was 12.4 percentage points.
What does the SELECT cardiovascular result mean?
SELECT studied adults aged 45 years or older who already had cardiovascular disease and had overweight or obesity but not diabetes. Major cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The hazard ratio of 0.80 is commonly expressed as a 20% relative risk reduction; the observed absolute difference was 1.5 percentage points during the study.
This is important outcome evidence, but it should not be oversold. It does not mean a 20% absolute benefit, it does not apply automatically to a young person without established cardiovascular disease, and it does not turn every semaglutide formulation into a cardiovascular treatment.
How does semaglutide compare with tirzepatide?
In the 2025 SURMOUNT-5 head-to-head trial, adults with obesity without diabetes had a mean weight reduction of 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. Mean waist reduction was 18.4 cm versus 13.0 cm. This is the clearest direct evidence for greater average weight efficacy with tirzepatide in the population studied.
It does not make semaglutide obsolete. Some patients may have a better indication, previous response, tolerance, affordability or supply pathway with semaglutide. Semaglutide also has the SELECT cardiovascular-outcome evidence in a defined high-risk population. A responsible decision compares the whole patient, not only the largest trial percentage.
When semaglutide may reasonably be considered
Semaglutide may be discussed for an appropriate approved indication after assessment of obesity severity, weight-related complications, diabetes status, cardiovascular history, previous treatment and the patient’s practical ability to continue therapy. It may be reasonable when experience or tolerability favours it, when its outcome evidence is particularly relevant, or when another option is unavailable or unsuitable.
It should not be prescribed solely because “Ozempic” is a familiar online word. The clinical question is not which product is most famous; it is which authorized treatment offers this patient the best balance of expected benefit, risk, continuity and cost.
What is assessed before a prescription decision?
- weight and waist history, previous treatment, regain and health-focused goals;
- diabetes or prediabetes, cardiovascular disease, blood pressure, lipids and fatty liver risk;
- current medicines, including insulin or sulfonylureas that can increase hypoglycaemia risk;
- gastrointestinal symptoms, hydration, gallbladder and pancreatic history where relevant;
- personal or family history relevant to thyroid C-cell tumour warnings and MEN2;
- pregnancy, breastfeeding and pregnancy plans;
- nutrition, protein, strength activity and risk of losing lean tissue;
- authentic product, licensed-pharmacy supply, cold-chain history, affordability and follow-up.
Safety and tolerability can decide the treatment
Common adverse effects include nausea, vomiting, diarrhoea, constipation, reduced appetite and abdominal discomfort. Clinically important concerns can include dehydration and kidney injury, gallbladder disease, pancreatitis, severe gastrointestinal problems, hypersensitivity and hypoglycaemia when used with certain glucose-lowering medicines. Product labels also include pregnancy considerations and the U.S. boxed warning concerning thyroid C-cell tumours observed in rodents, with contraindications for a personal or family history of medullary thyroid carcinoma or MEN2.
In SELECT, adverse events leading to permanent discontinuation occurred more often with semaglutide than placebo. That is a useful reminder that an effective medicine is not an effective plan if the patient cannot tolerate or continue it. The complete information for the exact authorized product must be reviewed.
Maintenance, nutrition and muscle cannot be afterthoughts
STEP 4 showed that participants who stopped after an initial semaglutide response regained weight, while those continuing lost more. Obesity treatment therefore needs a maintenance strategy from the beginning. That may include continued treatment when appropriate, nutrition and activity support, an alternative medicine, or metabolic-surgery referral for eligible patients.
Reduced appetite can also reduce protein, fluid and micronutrient intake. Dr. Fowad’s follow-up considers hydration, gastrointestinal symptoms, food adequacy, strength, waist, glucose and other metabolic measures rather than chasing the scale alone.
Counterfeit and unverified products are a real concern
DRAP has issued a safety alert about falsified GLP-1 receptor agonist products. Use only an authorized, verifiable product obtained from a licensed pharmacy with intact packaging, batch details and confirmed storage. Anonymous social-media sellers, unlabelled or repackaged syringes and products with no reliable cold chain should be avoided.
Dr. Fowad’s bottom line
Semaglutide is a scientifically important and clinically effective obesity medicine. The STEP programme demonstrates substantial average weight loss, and SELECT adds meaningful cardiovascular-outcome evidence in adults with established cardiovascular disease and overweight or obesity. Tirzepatide now produces greater average weight loss in head-to-head evidence, which is one reason it is more frequently used in Dr. Fowad’s current practice. The honest conclusion is not that one drug “wins” for every patient; it is that modern obesity care offers powerful options that must be matched to the individual and followed responsibly.
Frequently asked questions
Are Ozempic and every semaglutide product the same?
No. Semaglutide products can have different formulations, strengths and authorized indications. Ozempic is a U.S. diabetes brand and Wegovy is a U.S. weight-management brand. The exact product and current Pakistani status must be verified.
How much weight did people lose with semaglutide in STEP 1?
Adults without diabetes had an estimated average loss of 14.9% of starting body weight at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention, compared with 2.4% with placebo. Individual results vary and this was a defined clinical-trial protocol.
Does semaglutide reduce heart attacks and strokes?
In SELECT, adults with established cardiovascular disease and overweight or obesity, but without diabetes, had major cardiovascular events in 6.5% of the semaglutide group versus 8.0% with placebo. This 20% relative risk reduction applies to the population and product studied, not automatically to every patient.
Is tirzepatide more effective for weight loss?
In SURMOUNT-5, mean weight loss was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks in adults with obesity without diabetes. Suitability still depends on indication, safety, tolerability, cost, supply and patient preference.
Will weight return if semaglutide is stopped?
Weight regain is common after effective obesity medication is withdrawn. STEP 4 showed regain after participants switched from semaglutide to placebo. A maintenance strategy should be planned before treatment begins.
Primary sources
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, February 2021.
- STEP 2: Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes, The Lancet, March 2021.
- STEP 4: Continued semaglutide versus withdrawal for weight-loss maintenance, JAMA, March 2021.
- SELECT: Semaglutide and cardiovascular outcomes in obesity without diabetes, New England Journal of Medicine, November 2023.
- SURMOUNT-5: Tirzepatide compared with semaglutide for obesity, New England Journal of Medicine, May 2025.
- DRAP safety alert concerning falsified GLP-1 receptor agonists, July 2023.
Medical and regulatory note: This is an independent educational review, not a product advertisement, prescription or dosing guide. Trial averages do not guarantee an individual result. Brand indications and regulatory status differ by country and can change. Suitability requires an individual consultation, review of the complete information for the exact authorized product and a verifiable legal supply.